Anti-Tumor Necrosis Factor Blocking Agents in the Treatment of Systemic Vasculitis

Publisher： Bentham Science Publishers

E-ISSN： 1875-631x|7|4|423-428

ISSN： 1573-3955

Source： Current Immunology Reviews, Vol.7, Iss.4, 2011-11, pp. : 423-428

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Is polymyositis or dermatomyositis in patients with rheumatoid arthritis induced or unveiled by anti-tumor necrosis factor treatment?

By Nagashima Takao   Minota Seiji  

Clinical Rheumatology, Vol. 29, Iss. 7, 2010-07 ,pp. : 819-820

Springer Publishing Company

Access to resources Recommend Favorite

Treatment of Dermatomyositis and Polymyositis with Anti-Tumor Necrosis Factor-α: Long-Term Follow-Up

By  

European Neurology, Vol. 52, Iss. 1, 2004-07 ,pp. : 61-63

Karger

Access to resources Recommend Favorite

Patient’s Perspectives Important for Early Anti-Tumor Necrosis Factor Treatment in Inflammatory Bowel Disease

By  

Digestion, Vol. 79, Iss. 1, 2009-02 ,pp. : 30-35

Karger

Access to resources Recommend Favorite

Mechanism and Therapeutic Strategy of Secondary Failure to Anti-Tumor Necrosis Factor-α Monoclonal Antibody Treatment for Crohn's Disease

By  

Digestion, Vol. 88, Iss. 1, 2013-06 ,pp. : 17-19

Karger

Access to resources Recommend Favorite

Suspected de novo Hepatitis B in a Patient Receiving Anti-Tumor Necrosis Factor Alpha Therapy for the Treatment of Crohn's Disease

By  

Case Reports in Gastroenterology, Vol. 8, Iss. 1, 2014-01 ,pp. : 44-50

Karger

Access to resources Recommend Favorite